In the Claims:

Please amend the claims according to the claim listing below.

1. (original) A compound of Formula (**I**):



(**I**)

wherein:

X is NH or O;

R_1 is selected from the group consisting of H, halogen, hydroxy, thioxy, cyano, nitro, C_{1-4} haloalkyl, amino, C_{1-4} alkylamino, C_{2-8} dialkylamino, C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-5} cycloalkyl, C_{1-4} haloalkoxy, C_{1-4} alkylthio, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfonyl, C_{1-4} haloalkylthio, C_{1-4} haloalkylsulfinyl and C_{1-4} haloalkylsulfonyl;

R_2 is selected from the group consisting of H, halogen, hydroxy, thioxy, cyano, nitro, C_{1-4} haloalkyl, amino, C_{1-4} alkylamino, C_{2-8} dialkylamino, C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-5} cycloalkyl, C_{1-4} haloalkoxy, C_{1-4} alkylthio, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfonyl, C_{1-4} haloalkylthio, C_{1-4} haloalkylsulfinyl and C_{1-4} haloalkylsulfonyl; or R_2 is absent;

--- is a single bond when R_2 is present, or --- is a double bond when R_2 is absent; and

Ring A is a 5, 6 or 7-membered carbocyclic ring or a 5, 6 or 7-membered heterocyclic ring optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, hydroxy, thioxy, cyano, nitro, C_{1-4} haloalkyl, amino, C_{1-4} alkylamino, C_{2-8} dialkylamino, C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-5} cycloalkyl, C_{1-4} haloalkoxy, C_{1-4} alkylthio, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfonyl, C_{1-4} haloalkylthio, C_{1-4} haloalkylsulfinyl and C_{1-4} haloalkylsulfonyl; or

a pharmaceutically acceptable salt, solvate or hydrate thereof.

2. (original) The compound according to claim 1 wherein:

X is NH;

R_1 is H or hydroxy;

R_2 is H or absent;

--- is a single bond when R_2 is H, or --- is a double bond when R_2 is absent;

and

Ring A is a 5-membered carbocyclic ring or a 5-membered heterocyclic ring optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C_{1-4} alkyl, C_{1-4} alkoxy and C_{3-5} cycloalkyl; or

a pharmaceutically acceptable salt, solvate or hydrate thereof.

3. (original) The compound according to claim 1 having Formula (**If**):



(If)

wherein:

R_1 is H or hydroxy; and

Ring A is optionally substituted with 1 or 2 substituents selected from the group consisting of halogen, C_{1-4} alkyl, C_{1-4} alkoxy and C_{3-5} cycloalkyl; or

a pharmaceutically acceptable salt, solvate or hydrate thereof.

4. (original) The compound according to claim 1 having Formula (**Ih**):



(Ih)

wherein:

Ring A is optionally substituted with 1 or 2 substituents selected from the group consisting of halogen, C_{1-4} alkyl, C_{1-4} alkoxy and C_{3-5} cycloalkyl; or

a pharmaceutically acceptable salt, solvate or hydrate thereof.

5. (original) The compound according to claim 1 having Formula (**Ih**):



(Ih)

wherein:

Ring A is unsubstituted or is substituted with ethyl; or a pharmaceutically acceptable salt, solvate or hydrate thereof..

6. (original) The compound according to claim 1 having Formula (**Ih**):



(Ih)

wherein:

Ring A is substituted with 1 or 2 substituents selected from the group consisting of halogen, *n*-propyl, *n*-butyl, C_{1-4} alkoxy and C_{3-5} cycloalkyl; or

a pharmaceutically acceptable salt, solvate or hydrate thereof.

7. (original) The compound according to claim 1 that is 3-(1H-Tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

8. (original) The compound according to claim 1 that is 3-(1H-Tetrazol-5-yl)-2,6-dihydro-4H-thieno[3,4-c]pyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

9. (original) The compound according to claim 1 that is 6-Methyl-3-(1H-tetrazol-5-yl)-2,6-dihydro-4H-furo[3,4-c]pyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

10. (original) The compound according to claim 1 that is 3-(1H-Tetrazol-5-yl)-2,4-dihydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

11. (original) The compound according to claim 1 that is 3-(1H-Tetrazol-5-yl)-2,6-dihydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

12. (original) The compound according to claim 1 that is 3-(1H-Tetrazol-5-yl)-2,6-dihydro-4H-furo[3,4-c]pyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

13. (original) The compound according to claim 1 that is 5-Ethyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

14. (original) The compound according to claim 1 that is 5-Butyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

15. (original) The compound according to claim 1 that is 5-Methyl-3-(1H-tetrazol-5-yl)-2,6-dihydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

16. (original) The compound according to claim 1 that is 5-Methyl-3-(1H-tetrazol-5-yl)-2,4-dihydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

17. (original) The compound according to claim 1 that is 5-Propyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

18. (original) The compound according to claim 1 that is 5-Propoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

19. (original) The compound according to claim 1 that is 5-Cyclopentyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

20. (original) The compound according to claim 1 that is 5-Fluoro-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

21. (original) The compound according to claim 1 that is 5-Isobutoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

22. (original) The compound according to claim 1 that is 5-Butoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

23. (original) The compound according to claim 1 that is 3-(1H-Tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazol-6-ol or a pharmaceutically acceptable salt, solvate or hydrate thereof.

24. (original) The compound according to claim 1 that is 5-Methoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

25. (original) The compound according to claim 1 that is 5,5-Difluoro-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

26. (original) The compound according to claim 1 that is 5-Ethoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

27. (currently amended) A pharmaceutical composition comprising a compound according to ~~any one of claims 1 to 26~~ claim 1 in combination with a pharmaceutically acceptable carrier.

28. (currently amended) A method of treatment of a metabolic-related disorder comprising administering to an individual in need of such treatment a therapeutically-effective amount of a compound according to ~~any one of claims 1 to 26~~ claim 1.

29. (currently amended) The method according to claim ~~27~~ 28 wherein said metabolic-related disorder is selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.

30. (currently amended) The method according to claim ~~27~~ 28 wherein said metabolic-related disorder is atherosclerosis.

31. (currently amended) A method of raising HDL in an individual comprising administering to said individual a therapeutically-effective amount of a compound according to ~~any one of claims 1 to 26~~ claim 1.

32.-40. (canceled)

41. (currently amended) A method of producing a pharmaceutical composition comprising admixing a compound according to ~~any one of claims 1 to 26~~ claim 1 and a pharmaceutically acceptable carrier.

42. (new) The compound of claim 1 wherein Ring A is a 5, 6 or 7 membered heterocyclic ring containing one group selected from O, S, S(O), and $S(O)_2$.